Hepatic ChREBP reciprocally modulates systemic insulin sensitivity in NAFLD
Journal of Biological Chemistry · 2025-06 · 301 (6) · 108556
DOI: 10.1016/j.jbc.2025.108556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-06. Verfasst von Aniket Sen und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Biosciences and Bioengineering, IIT Mandi, Mandi, India. Hauptthemen laut MEDLINE: Insulin Resistance, Non-alcoholic Fatty Liver Disease, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science for Equity, Empowerment and Development Division, Department of Biotechnology, Ministry of Science and Technology, India, University Grants Commission.
Abstract (Originalsprache)
The relation between hepatic ChREBP level and insulin sensitivity remains equivocal. Our study, however, provides compelling evidence that hepatic ChREBP depletion can significantly enhance insulin sensitivity in high-fat and sucrose-fed mice. We have identified that transcriptional induction of hepatic PTEN is driven by ChREBP. Mechanistically, two critical stimuli are elicited in the hepatic ChREBP knockdown condition. The PTEN level is reduced for one stimulus, thereby promoting hepatic insulin sensitivity. The second stimulus, where reduced hepatic PTEN leads to the enhanced release of FGF21, spreads systemic insulin sensitivity. These findings identify hepatic ChREBP as a critical modulator of systemic insulin signaling and suggest that ChREBP downregulation may lead to protection against insulin resistance. Building on this, our molecular dynamics simulation analysis has led to the discovery of a small molecule, Quercetin, that sequesters ChREBP in the cytosol. We report that Quercetin treatment can sequester ChREBP in the cytosol and abrogate high-fat and sucrose-fed-mediated ChREBP nuclear translocation, thereby mimicking the insulin-sensitizing abilities of the hepatic ChREBP knockdown condition. These findings have significant therapeutic implications, suggesting that liver-selective downregulation of ChREBP could protect against systemic insulin resistance that frequently develops early in the pathogenesis of NAFLD and T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biosciences and Bioengineering, IIT Mandi, Mandi, India.
- Department of Biological Sciences, Indian Institute of Science Education and Research Berhampur (IISER Berhampur), Berhampur, India.
- Department of Bioinformatics, Manipal School of Life Sciences, Manipal Academy of Higher Education, Karnataka, India.
- Department of Biological Sciences, Indian Institute of Science Education and Research Berhampur (IISER Berhampur), Berhampur, India. Electronic address: pmondal@iiserbpr.ac.in.
Förderung
- Science for Equity, Empowerment and Development Division
- Department of Biotechnology, Ministry of Science and Technology, India
- University Grants Commission
- Science and Engineering Research Board
Zitieren
APA
Sen, A., Thakur, S., Rawat, P., Jaswal, K., Dehury, B., & Mondal, P. (2025). Hepatic ChREBP reciprocally modulates systemic insulin sensitivity in NAFLD. Journal of Biological Chemistry, 301(6), 108556. https://doi.org/10.1016/j.jbc.2025.108556
Vancouver
Sen A, Thakur S, Rawat P, Jaswal K, Dehury B, Mondal P. Hepatic ChREBP reciprocally modulates systemic insulin sensitivity in NAFLD. Journal of Biological Chemistry. 2025;301(6):108556. doi:10.1016/j.jbc.2025.108556
BibTeX
@article{Sen2025,
author = {Sen, Aniket and Thakur, Shilpa and Rawat, Priya and Jaswal, Kajal and Dehury, Budheswar and Mondal, Prosenjit},
title = {Hepatic ChREBP reciprocally modulates systemic insulin sensitivity in NAFLD},
journal = {Journal of Biological Chemistry},
year = {2025},
volume = {301},
number = {6},
pages = {108556},
doi = {10.1016/j.jbc.2025.108556}
}
EUVIMED